Thalidomide Celgene-H-C-PSUSA-00002919-201910: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Thalidomide Celgene-H-C-PSUSA-00002919-201910: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Fortschrittliche pharmazeutische Formulierung für gezielte therapeutische Intervention.
Dosierung
Thalidomide Celgene-H-C-PSUSA-00002919-201910: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Stärke
Thalidomide Celgene-H-C-PSUSA-00002919-201910: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Packungsgröße
Thalidomide Celgene-H-C-PSUSA-00002919-201910: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Form
Thalidomide Celgene-H-C-PSUSA-00002919-201910: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Quelle
European Medicines Agency
Sicherheitsprofil
Kontraindikationen
Nebenwirkungen
Scanne diesen QR-Code, um schnell auf diese Seite auf deinem Mobilgerät zuzugreifen.